TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma
© Kuwahara et al; licensee BioMed Central Ltd. 2010
Received: 14 June 2010
Accepted: 20 July 2010
Published: 20 July 2010
Currently definitive 5-fluorouracil (5-FU)/cisplatin (CDDP) -based chemotherapy is recognized as one of the most promising treatments for esophageal cancer. A series of studies performed found genetic polymorphisms and the plasma concentration of 5-FU to be predictive of acute severe toxicities and clinical response. Genetic polymorphisms of tumor necrosis factor (TNF) -α and its surface receptors, TNFRSF1A and TNFRSF1B have been examined in terms of susceptibility to various cancers. In this study, genetic polymorphisms of TNFRSF1B gene were evaluated Japanese esophageal squamous cell carcinoma (ESCC) patients treated with the definitive 5-FU/CDDP-based chemoradiotherapy and their predictive values of prognosis or severe acute toxicities were assessed.
Forty-six patients with ESCC were treated with the definitive 5-FU/CDDP-based chemoradiotherapy, one course of which consisted of the continuous infusion of 5-FU for days 1-5 and 8-12, the infusion of CDDP on days 1 and 8, and the radiation at 2 Gy/day on days 1-5, 8-12, and 15-19, with a second course repeated after 2-week interval. Genetic polymorphisms of a TNF-α receptor TNFRSF1B gene were determined by a TaqMan® MGB probe-based polymerase chain reaction.
The genotype of TNFSR1B A1466G, but not M196R/T587G or C1493T, was found to be predictive of clinical response, i.e., a complete response or not (p = 0.040). Clinical response was predicted by tumor size (p = 0,002), lymph node metastasis (p = 0.007), distant metastasis (p = 0.001) and disease stage (p < 0.001), but TNFRSF1B A1466G genotype was independent of these factors.
Genetic polymorphism of TNFRSF1B A1466G was found to be predictive response in Japanese ESCC patients with a definitive 5-FU/CDDP-based chemoradiotherapy. Further clinical investigation with a large number of patients or experiments in vitro should be performed to assess the predictive value of TNFRSF1B A1466G genotype after chemoradiotherapy.
A clinical report published in 1999, the RTOG (Radiation Therapy Oncology Group) 85-01 trial involving 134 patients with T1-3, N0-1 and M0 esophageal cancer, is of great interest in terms of clinical outcome because it demonstrated a 5-year survival rate of 26% . This treatment consists of infusions of 5-fluorouracil (5-FU) and cisplatin (CDDP), and concurrent radiation, without pre- or post-surgical resection. Simultaneously in Japan, a modified version was proposed by Ohtsu and his co-workers for advanced metastatic esophageal cancer [2, 3]. Two independent clinical investigations have shown curative potential using this regimen for unresectable esophageal squamous cell carcinoma (ESCC) of T4 or M1a [2, 3]. A long-term evaluation of efficacy and toxicity with 139 patients revealed a complete response (CR) rate of 56%, along with a 5-year survival rate of 29% [4, 5]. Currently, definitive 5-FU/CDDP-based chemoradiotherapy is recognized as one of the most promising treatments for esophageal cancer . A series of studies performed to find a marker predictive of clinical outcome after treatment with a definitive 5-FU/CDDP-based chemoradiotherapy found a genetic polymorphism, G-1154A, of vascular endothelial growth factor to be a predictor of severe acute leukopenia and cheilitis, and the plasma concentration of 5-FU to be predictive of clinical response [7–9].
Tumor necrosis factor (TNF)-α, a proinflammatory cytokine, plays a key role in the pathogenesis of inflammatory diseases. Its biological effects are elicited by binding to its two cognate cell surface receptors, TNFRSF1A/TNFR1 (p55/60) and TNFRSF1B/TNFR2 (p75/80), both of which are involved in increasing expression of other cytokines and immuno-regulatory molecules through the activation of nuclear factor κB. Through extensive examinations of expression and function, some genetic variations have been shown to explain inter-individual variation. Single nucleotide polymorphisms (SNPs) in the TNF-α, TNFRSF1A and TNFRSF1B genes have been identified, however functional data pertaining to these polymorphisms in scarce. Nonetheless, the putative role of these polymorphisms in disease susceptibility has been examined in genetic association studies of various inflammatory disorders, including Crohn's disease [10–13], ulcerative colitis [10, 11, 14], systemic lupus erythematosus [15–17] and rheumatoid arthritis [18, 19]. More recently, given that cancer progression is preceded by a long period of subclinical inflammation [20–22], the genetic polymorphisms of TNF-α, TNFRSF1A and TNFRSF1B have been examined in terms of susceptibility to various cancers [23–28]. In this study, genetic polymorphisms of the TNFRSF1B gene, M196R/T587G, A1466G and C1493T, were evaluated in Japanese ESCC patients treated with a definitive 5-FU/CDDP-based chemoradiotherapy, and their predictive values of prognosis or severe acute toxicities were assessed. To our knowledge, this is the first paper to report that the TNFRSF1B genotype is predictive of the clinical efficacy of cancer chemoradiotherapy.
Forty-six male ESCC patients were enrolled in this study based on the following criteria: 1) ESCC treated with a definitive 5-FU/CDDP-based chemoradiotherapy at Kobe University Hospital, Japan, from August 2002 to June 2006; 2) clinical stage T1 to T4, N0 or N1, and M0 or M1a according to the International Union Against Cancer tumor-node-metastasis (TNM) classification; 3) age less than 85 years; 4) an Eastern Cooperative Oncology Group performance status of 0 to 2; 5) adequate bone marrow, renal, and hepatic function; 6) no prior chemotherapy; 7) no severe medical complications; and 8) no other active malignancies (except early cancer). The tumors were histologically confirmed to be primary, and no patients with recurrence were included in this study. Written informed consent was obtained from all participants prior to enrollment. This study was conducted with the authorization of the institutional review board and followed the medical research council guidelines of Kobe University.
Genomic DNA was isolated from whole blood with a TaqMan® Sample-to-SNP™ kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's directions. Genetic polymorphisms of TNFRSF1B; M196R/T587G, A1466G and C1493T, were determined by a TaqMan® MGB probe-based polymerase chain reaction (PCR) using the StepOne™ real-time PCR system (Applied Biosystems) and pre-manufactured TaqMan® SNP genotyping assays C_8861232_20 (M196R/T587G, rs1061622), C_8861229_10 (A1466G, rs1061624) and C_8861228_20 (C1493T, rs3397) (Applied Biosystems). The PCR was carried out according to the manufacturer's protocol. For each set of reactions, DNA of cases and controls was taken and a negative control containing H2O instead of DNA was added to check for contamination.
The clinical response was evaluated according to the method reported previously [2–5]. Briefly, a CR was defined as the complete disappearance of all measurable and assessable disease at the first evaluation, which was performed 1 month after the completion of chemoradiotherapy to determine whether the disease had progressed. The clinical response was evaluated by endoscopy and chest and abdominal computed tomography (CT) scans in each course. A CR at the primary site was evaluated by endoscopic examination when all of the following criteria were satisfied on observation of the entire esophagus: 1) disappearance of the tumor lesion; 2) disappearance of ulceration (slough); and 3) absence of cancer cells in biopsy specimens. If small nodes of 1 cm or less were detected on CT scans, the recovery was defined as an "uncertain CR" after confirmation of no progression for at least 3 months. An "uncertain CR" was included as a CR when calculating the CR rate. When these criteria were not satisfied, a non-CR was assigned. The existence of erosion, a granular protruded lesion, an ulcer scar, and 1.2 w/v% iodine/glycerin-voiding lesions did not prevent an evaluation of CR. The evaluations were performed every month for the first 3 months, and when the criteria for CR were not satisfied at 3 months, the result was changed to non-CR. Follow-up evaluations were performed thereafter every 3 months for 3 years by endoscopy and CT scan. After 3 years, patients were seen every 6 months. During the follow-up period, a routine course of physical examinations and clinical laboratory tests was performed to check the patient's health.
Severe acute toxicities
Definitive 5-FU/CDDP-based chemoradiotherapy is associated with acute toxicities; leucopenia, anemia, thrombocytopenia, nausea/vomiting, diarrhea, mucositis (including stomatitis), esophagitis, and renal dysfunction [2–5]. Here, severe acute leucopenia, stomatitis, and cheilitis were subjected to analysis. Toxicity was evaluated using criteria defined by the Japan Clinical Oncology Group . These criteria were based on the National Cancer Institute Common Toxicity Criteria. Toxicity was assessed on a 2 to 3-day basis during the chemoradiotherapy and subsequent hospitalization period and on every visit after the completion of chemoradiotherapy. Episodes of leucopenia, stomatitis, and cheilitis during the first 2 courses and subsequent 2 weeks (until day 70) were recorded as acute toxicities and those of grade 3 or more as severe acute toxicities.
Survival after the chemoradiotherapy
The survival period was defined as the time from the date of treatment initiation to that of death from any causes or to the last date of confirmation of survival. Survival data were updated on December 31, 2006, and the 2-year survival rate was assessed using the data for 36 patients.
Data analysis and statistics
All values reported are the mean ± standard deviation (SD). The unpaired Student's t-test/Welch's test or Mann-Whitney's U test was used for two-group comparisons of the concentrations. Fisher's exact test was used for the analysis of contingency tables. The difference of overall survival curves was analyzed by Log-rank test. P values of less than 0.05 (two tailed) were considered to be significant.
Demographic and clinicopathologic characteristics of Japanese patients with esophageal squamous cell carcinoma.
64.6 ± 7.2 (range 48-78)
164.2 ± 6.2 (range 152-180)
56.7 ± 9.6 (33-79)
Performance status, 0/1/2/unknown
Effects of TNFRSF1B polymorphisms on clinical response in Japanese patients with esophageal squamous cell carcinoma.
N = 22
Not complete response
N = 24
The TNFRSF1B gene on chromosome 1 at p36 (IBD7) consists of 10 exons and encodes 415 amino acids, whereas the TNFRSF1A gene at 12p13 (IBD2) consists of 10 exons and encodes 455 amino acids. TNFRSF1A is an important factor inducing apoptosis via an intracellular death domain, and TNFRSF1B is thought to be involved in ligand passing, thereby regulating the association of TNF-α with TNFRSF1A. TNFRSF1A is widely expressed, whereas TNFRSF1B is predominantly expressed in cells of the hematopoietic lineage. Several clinical investigations have been conducted to assess the predictive value of the genetic polymorphisms TNF-α G-308A, TNFRSF1A A36G and G-609T, and TNFRSF1B M196R/T587G, A1466G (or A1663G) and C1493T (or C1690T) regarding susceptibility to various inflammatory disorders [10–19], and recently, to cancer [23–28]. As for TNFRSF1B, the SNP M196R/T587G has proved predictive of Crohn's disease , systemic lupus erythematosus [15–17] and rheumatoid arthritis . TNFRSF1B A1466G is not associated with Crohn's disease , but the haplotype 1466A-1493T might be important . Recently, TNFRSF1B C1493T has been found to be a risk factor of tobacco-related oral carcinoma .
In this study, it was demonstrated that the TNFRSF1B A1466G genotype was a predictive factor of clinical response to treatment with a definitive 5-FU/CDDP-based chemoradiotherapy in Japanese ESCC patients. The TNFRSF1B G-allele at position 1466 is predictive of clinical response, whereas no such association was found for M196R/T587G or C1493T (Table 2). Clinical response was evaluated 1 month after the completion of the chemoradiotherapy, and a CR was defined as the complete disappearance of all measurable and assessable disease. Clinical response was determined by T class (an index of tumor size, p = 0.002), N class (lymph node metastasis, p = 0.007), M class (distant metastasis, p = 0.001) and disease stage (p < 0.001), but TNFRSF1B A1466G genotype was independent of these factors.
Clinical response was significantly associated with overall survival (Figure 2), however, TNFRSF1B A1466G genotype had no effect on the overall survival, presumably because it was not associated with death within 1 year after the completion of chemoradiotherapy. There is no report on the function of this polymorphism but it has been reported that higher expression levels of TNFRSF1B gene in colorectal cancer specimens from responding patients were observed compared with those from non-responding patients . Thus, the polymorphism-dependent clinical response might be due to the polymorphism-dependent expression levels, although further studies are needed.
Genetic polymorphisms of the TNFRSF1B gene, M196R/T587G, A1466G and C1493T, were evaluated in Japanese ESCC patients treated with a definitive 5-FU/CDDP-based chemoradiotherapy. It was found that A1466G, but not M196R/T587G or C1493T, was a predictive factor of clinical response to chemoradiotherapy. Clinical response was predicted by TNM classes and disease stage, but A1466G genotype was independent of these factors. Further clinical investigation with a large number of patients or experiments in vitro should be performed to assess the predictive value of TNFRSF1B A1466G genotype after chemoradiotherapy.
This work was supported in part by a Grant-in-Aid for Scientific Research and Service Innovation Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
- Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999, 281: 1623-1627. 10.1001/jama.281.17.1623.View ArticleGoogle Scholar
- Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999, 17: 2915-2921.Google Scholar
- Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A, Mitamura K: Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003, 88: 18-24. 10.1038/sj.bjc.6600684.View ArticleGoogle Scholar
- Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S: Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005, 35: 316-323. 10.1093/jjco/hyi095.View ArticleGoogle Scholar
- Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003, 21: 2697-2702. 10.1200/JCO.2003.03.055.View ArticleGoogle Scholar
- Sakaeda T, Yamamori M, Kuwahara A, Nishiguchi K: Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev. 2009, 61: 388-401. 10.1016/j.addr.2008.10.005.View ArticleGoogle Scholar
- Miki I, Tamura T, Nakamura T, Makimoto H, Hamana N, Uchiyama H, Shirasaka D, Morita Y, Yamada H, Aoyama N, Sakaeda T, Okumura K, Kasuga M: Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit. 2005, 27: 369-374. 10.1097/01.ftd.0000162554.23501.e6.View ArticleGoogle Scholar
- Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T: Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for Stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol. 2007, 30: 252-257. 10.1097/01.coc.0000256059.88247.25.View ArticleGoogle Scholar
- Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T: VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit. 2008, 30: 497-503.Google Scholar
- Cucchiara S, Latiano A, Palmieri O, Canani RB, D'Incà R, Guariso G, Vieni G, De Venuto D, Riegler G, De'Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, Bossa F, Annese V, Italian Society of Pediatric Gastroenterology and Nutrition: Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007, 44: 171-179. 10.1097/MPG.0b013e31802c41f3.View ArticleGoogle Scholar
- Sashio H, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T, Fukui S, Sawada K, Fukuda Y, Tamura K, Satomi M, Shimoyama T, Furuyama J: Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics. 2002, 53: 1020-1027. 10.1007/s00251-001-0423-7.View ArticleGoogle Scholar
- Sýkora J, Subrt I, Dìdek P, Siala K, Schwarz J, Machalová V, Varvarovská J, Pazdiora P, Pozler O, Stozický F: Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G>A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease. J Pediatr Gastroenterol Nutr. 2006, 42: 479-487. 10.1097/01.mpg.0000221917.80887.9e.View ArticleGoogle Scholar
- Waschke KA, Villani AC, Vermeire S, Dufresne L, Chen TC, Bitton A, Cohen A, Thomson AB, Wild GE: Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes. Am J Gastroenterol. 2005, 100: 1126-1133. 10.1111/j.1572-0241.2005.40534.x.View ArticleGoogle Scholar
- Lu Z, Chen L, Li H, Zhao Y, Lin L: Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Digestion. 2008, 78: 44-51. 10.1159/000158605.View ArticleGoogle Scholar
- Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, Kyushu Sapporo SLE (KYSS) Study Group: Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population. J Rheumatol. 2009, 36: 2195-2203. 10.3899/jrheum.090181.View ArticleGoogle Scholar
- Horiuchi T, Kiyohara C, Tsukamoto H, Sawabe T, Furugo I, Yoshizawa S, Ueda A, Tada Y, Nakamura T, Kimoto Y, Mitoma H, Harashima S, Yoshizawa S, Shimoda T, Okamura S, Nagasawa K, Harada M: A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis. Ann Rheum Dis. 2007, 66: 320-324. 10.1136/ard.2006.058917.View ArticleGoogle Scholar
- Horiuchi T, Washio M, Kiyohara C, Tsukamoto H, Tada Y, Asami T, Ide S, Kobashi G, Takahashi H, Kyushu Sapporo SLE Study Group: Combination of TNF-RII, CYP1A1 and GSTM1 polymorphisms and the risk of Japanese SLE: findings from the KYSS study. Rheumatology (Oxford). 2009, 48: 1045-1049. 10.1093/rheumatology/kep166.View ArticleGoogle Scholar
- Barton A, John S, Ollier WE, Silman A, Worthington J: Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. Arthritis Rheum. 2001, 44: 61-65. 10.1002/1529-0131(200101)44:1<61::AID-ANR9>3.0.CO;2-Q.View ArticleGoogle Scholar
- Glossop JR, Dawes PT, Hassell AB, Mattey DL: Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes. J Rheumatol. 2005, 32: 1673-1678.Google Scholar
- Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nature Rev Immunol. 2004, 4: 641-648. 10.1038/nri1415.View ArticleGoogle Scholar
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.View ArticleGoogle Scholar
- Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T: TRAIL-induced apoptosis: between tumor therapy and immunopathology. Ann N Y Acad Sci. 2009, 1171: 50-58. 10.1111/j.1749-6632.2009.04905.x.View ArticleGoogle Scholar
- Canova C, Hashibe M, Simonato L, Nelis M, Metspalu A, Lagiou P, Trichopoulos D, Ahrens W, Pigeot I, Merletti F, Richiardi L, Talamini R, Barzan L, Macfarlane GJ, Macfarlane TV, Holcátová I, Bencko V, Benhamou S, Bouchardy C, Kjaerheim K, Lowry R, Agudo A, Castellsagué X, Conway DI, McKinney PA, Znaor A, McCartan BE, Healy CM, Marron M, Brennan P: Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project. Cancer Res. 2009, 69: 2956-2965. 10.1158/0008-5472.CAN-08-2604.View ArticleGoogle Scholar
- Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Patsouris E: Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2008, 134: 821-832. 10.1007/s00432-008-0360-z.View ArticleGoogle Scholar
- Colakogullari M, Ulukaya E, Yilmaztepe Oral A, Aymak F, Basturk B, Ursavas A, Oral HB: The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct. 2008, 26: 283-290. 10.1002/cbf.1419.View ArticleGoogle Scholar
- Yapijakis C, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW, Patsouris E, Vairaktaris E: Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer. Anticancer Res. 2009, 29: 2379-2386.Google Scholar
- Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Saito H, Minamiya Y, Satoh S, Murata K, Suzuki T, Ogawa J: CRP genetic polymorphism is associated with lymph node metastasis in thoracic esophageal squamous cell cancer. Ann Surg Oncol. 2009, 16: 2479-2485. 10.1245/s10434-009-0525-2.View ArticleGoogle Scholar
- Gupta R, Sharma SC, Das SN: Association of TNF-alpha and TNFR1 promoters and 3' UTR region of TNFR2 gene polymorphisms with genetic susceptibility to tobacco-related oral carcinoma in Asian Indians. Oral Oncol. 2008, 44: 455-463. 10.1016/j.oraloncology.2007.06.003.View ArticleGoogle Scholar
- Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, Narabayashi M, Fukutomi T, Kondo H, Shimoyama M, Suemasu K, Members of the Clinical Trial Review Committee of the Japan Clinical Oncology Group: Toxicity grading criteria of the Japan Clinical Oncology Group (The Clinical Trial Review Committee of the Japan Clinical Oncology Group). Jpn J Clin Oncol. 1993, 23: 250-257.Google Scholar
- Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, Endo I, Kunisaki C, Suzuki H, Hayasizaki Y, Shimada H: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer. 2006, 119: 406-13. 10.1002/ijc.21843.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.